Comprehensive genomic profiling from
a blood sample. Fast.
Easy to interpret report informs first-line decisions and beyond

Blood Sample
2x 10 ml tubes of blood
7 days
Comprehensive genomic
profiling results in
only 7 days
Take action
Clinically relevant alterations
in 70+ cancer related genes.
For patients with advanced solid tumour cancers
-
Before 1st Line Treatment
Get ahead of the challenges of tissue testing in advanced NSCLC by utilizing Guardant360 to guide 1st line treatment decisions
-
At Progression
Get genomic information on over 70+ genes, including MSI across multiple solid tumors to help find cancer therapies and clinical trials.
PUBLISHED DATA
Prospective study of 323 NSCLC patients found Guardant360 improved alteration detection1 1. Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 2018 Oct 11. doi: 10.1001/jamaoncol.2018.4305. [Epub ahead of print.]
were unable to get complete genomic results from tissue biopsy
had targetable alterations detected by Guardant360 and tissue testing (n=82) versus tissue testing alone (n=47)
treated based on Guardant360 had a response or stable disease